PYC Therapeutics (PYC) investor relations material

Executive summary

• Recent financing has significantly strengthened the balance sheet, enabling advancement of four pipeline assets targeting severe genetic diseases with high unmet need, leveraging genetically validated targets and patient-derived models to de-risk development.

• Focuses on RNA therapeutics for haploinsufficient diseases with delivery challenges overcome, with three programs in clinical trials and a fourth expected to enter human trials in H1 2027.

• Tier 1 specialist investors have joined, aligning incentives and providing strategic industry connections.

• Ended Q1 2026 with $667 million in cash, plus a $23 million R&D rebate received in April.

Financial highlights

• Successful capital raise results in a cash balance exceeding $750 million, ensuring operational funding through calendar year 2030.

• Raised $600 million from equity issuance, offset by $36.9 million in transaction costs.

• Cash and cash equivalents at quarter end totaled $666.7 million.

• Estimated 41 quarters of funding available at current burn rate.

• Strong shareholder register with substantial new investment, including AUD 333.3 million worth of stock allocated to new investors at the same price as the entitlement offer.

Outlook and guidance

• Multiple near-term human efficacy readouts expected within the next 24 months for all four drug candidates, with key milestones mapped through 2030.

• Preparing for multiple clinical milestones in 2026 and 2027, including human trial initiations and key efficacy readouts.

• IND submission for Phelan-McDermid Syndrome program expected in H1 2027.

• Ophthalmology programs (RP11 and ADOA) are awaiting long-term efficacy data and regulatory alignment before phase III initiation.